- 98 - we plan to ( i ) continue investing in our infrastructure , including but not limited to solution development , sales and marketing , implementation and support , ( ii ) continue efforts to make infrastructure investments within an overall context of maintaining reasonable expense discipline , ( iii ) add new clients through maintaining and expanding sales , marketing and solution development activities , ( iv ) expand our relationships with existing clients through delivery of add-on and complementary solutions and services and ( v ) continue our commitment of service in support of our client satisfaction programs . we believe that our growing client base using our nantos and nantos apps on a daily basis is a strategic asset , and we intend to expand sales of nanthealth solutions offerings towards this client base in order to leverage this strategic asset . recent developments on june 7 , 2016 , we completed our ipo , whereby we sold 6,500,000 shares of our common stock at a public offering price of $ 14.00 per share . additionally , on june 9 , 2016 , the underwriters partially exercised their overallotment option to purchase an additional 400,000 shares of our common stock at $ 14.00 per share . we received a total of $ 83.6 million in net proceeds from our ipo , after deducting underwriting discounts and commissions and offering costs of $ 13.0 million . the offering was registered under the securities act of 1933 , as amended , on a registration statement on form s-1 ( registration no . 333-211196 ) , as amended . in december 2016 , we issued convertible notes to a related party and others for net proceeds of $ 9.9 million and $ 92.8 million , respectively , after deducting underwriting discounts and commissions and other offering costs of $ 4.2 million . please see note 12 of the notes to consolidated and combined financial statements included in item 8 of this annual report on form 10-k for further discussion of these convertible notes . recent acquisitions and investments we have made several significant acquisitions and investments in 2014 , 2015 and 2016 , which have expanded the features and functionality of nanthealth solutions , including the following : ndo in june 2014 , we acquired ndo , which provides healthcare interoperability and informatics solutions through its cos platform to address population health issues . our results of operations include the impact of the ndo acquisition as of june 2014. nantomics in june 2015 , we invested a substantial portion of our available capital in nantomics , a majority owned subsidiary of nantworks . our investment represents approximately 14.3 % of the issued and outstanding membership interests of nantomics . our relationship with nantomics provides us with access to what we believe is the nation 's only cap- and clia-certified whole genome and quantitative proteomics laboratory . healthcare solutions ( “ hcs ” ) in july 2015 , we acquired certain assets related to hcs business from harris corporation . we believe the acquired assets will help complex healthcare delivery organizations achieve better patient outcomes , clinical and administrative workflow efficiency and stronger collaboration across the continuum of care . navinet in january 2016 , we acquired navinet , which provides a secure collaboration network connecting approximately 36 health plans and which is estimated to be utilized in more than 70 % of the nation 's physicians ' offices during the fourth quarter of 2016. navinet open will serve as a nationwide scalable and secure web-based portal for patients and providers . non-gaap net loss and non-gaap net loss per share adjusted net loss and adjusted net loss per share are financial measures that are not prepared in conformity with united states generally accepted accounting principles ( u.s. gaap ) . our management believes that the presentation of non-gaap financial measures provides useful supplementary information regarding operational performance , because it enhances an investor 's overall understanding of the financial results for our core business . additionally , it provides a basis for the comparison of the financial results for our core business between current , past and future periods . other companies may define these measures in different ways . non-gaap financial measures should be considered only as a supplement to , and not as a substitute for or as a superior measure to , financial measures prepared in accordance with u.s. gaap . all loss per share numbers contained in this annual report on form 10-k are calculated based on one class of common stock and do not incorporate the effects , if any , of using the two-class method . - 99 - adjusted net loss excludes the effects of ( 1 ) loss from equity method investments , ( 2 ) stock based compensation expense , ( 3 ) intangible amortization , ( 4 ) corporate restructuring expenses , ( 5 ) bp settlement other income , ( 6 ) acquisition related compensation expense , ( 7 ) acquisition-related sales incentives , which have been recorded as contra revenue , ( 8 ) change in fair value of derivatives liability , ( 9 ) non-cash interest expense related to convertible notes , and ( 10 ) benefit for ( provision from ) income taxes adjustment includes the impact of the conversion from a limited liability corporation to a corporation , the impact of convertible notes offering and the impact of intangibles amortization . adjusted shares outstanding include series f redeemable shares as if converted on january 1 , 2014 . story_separator_special_tag this decrease was offset by a $ 1.0 million incremental increase as a result of the hcs acquisition . in 2015 , there were more projects in excess of $ 1.0 million dollars in contract value completed compared with to 2016 . we believe opportunities exist to grow software and hardware revenue through completion of both existing implementations as well as executing new sales bookings from our pipeline of opportunities . saas revenue was $ 58.4 million for the year ended december 31 , 2016 , an increase of $ 37.6 million or 181.5 % from $ 20.7 million compared to the prior year . this increase was primarily driven by increased nantos revenue including $ 1.0 million of fusionfx revenue acquired with the acquisition of hcs assets in july 2015 and revenue of $ 41.0 million from the acquisition of navinet in january 2016 in connection with saas revenue . in addition , revenue from our nantos cancer decision support ( formerly eviti ) platform solutions increased $ 1.5 million , partially offset by a $ 5.7 million decrease in revenue from other nantos interoperability platforms . maintenance revenue increased $ 3.8 million or 36.2 % from $ 10.5 million in the year ended december 31 , 2015 to $ 14.2 million for the year ended december 31 , 2016 . this increase was primarily driven by the acquisition of hcs assets in july 2015. acquired nantos ( formerly harris hcs ) maintenance customers contributed to an increase of $ 3.9 million in maintenance revenue for the year ended december 31 , 2016 . - 107 - sequencing and molecular analysis revenue during the period included revenue recognized for gps profiles for which fees are fixed and determinable under a payor agreement as well as what was recognized on a cash basis due to uncertainty over reimbursement . for the year ended december 31 , 2016 , we recorded $ 0.6 million in sequencing and molecular analysis revenue . there are significant opportunities going forward as we gain momentum in gaining coverage in the us with commercial health plans and self-insured employers and globally with supplemental benefits insurers , while at the same time building gps adoption among oncologists , including the community and academic institutions . we are aggressively expanding our sales efforts by adding seasoned sales and account management professionals in 2017. the commercial team 's efforts are focused around the development of pilots with commercial insurance payers who would agree to pay for a certain number of gps profiles , aligned with designated provider groups who will order the gps test , and reimbursement is recognized . the pipeline of pilot opportunities going into 2017 is in excess of $ 10.0 million dollars . our pipeline of self-insured employers includes opportunities with many companies listed on fortune 's 100 , as well as an alliance of 50 of the largest employers in the us . most recently , we announced a partnership with the international association of firefighters , which is significant not only because of its size , but because its incidence of cancer is much greater than the average population , and in 37 states , there are presumptive laws around job related cancer for firefighters , which has opened discussions for us related to worker 's compensation as well . other services revenue increased $ 6.5 million or 52.4 % from $ 12.4 million in 2015 to $ 18.9 million for the year ended december 31 , 2016 . this was primarily driven by the completion of a large nantos interoperability ( formerly harris hcs ) software related services project which contributed to nantos interoperability services revenue growth of $ 8.6 million for the year ended december 31 , 2016 , and incremental growth of $ 0.2 million from the navinet acquisition . these increases were partially offset by a $ 2.1 million decrease of nantos deviceconx solutions due to a decline in the number of completed large projects . we believe that significant opportunities exist for expanded cross-sell opportunities of our suite of solutions across our existing customer base , including the recently acquired hcs fusionfx and navinet customer bases . we are also integrating the cos , fusionfx and navinet product solutions , within our nantos platform , and believe that opportunities exist to cross-sell this combination of solutions to existing former hcs , fusionfx and navinet customers as well as to new customers . we also believe that our customer base and our product solutions provide unique opportunities to expand the volume of gps sequencing analysis reporting to our customer base . maintaining our current customer base will be important to our future maintenance and saas recurring revenue streams . comparison of the years ended december 31 , 2014 and 2015 total revenue increased $ 24.4 million , or 71.9 % , from $ 33.9 million for the year ended december 31 , 2014 to $ 58.3 million for the year ended december 31 , 2015 . our total revenue growth came in all of our revenue categories and was driven primarily by growth in our existing solutions including nantos ( deviceconx and cos ) , eviti and sequencing and molecular analysis , as well as our acquisition of hcs assets in july 2015. our acquisition of certain assets of hcs resulted in the contribution of $ 1.0 million , $ 1.1 million and $ 2.9 million in saas , maintenance and other services revenue , respectively , for the year ended 2015 . our total software-related revenue ( including software , hardware , and saas ) increased to $ 35.4 million for 2015 from $ 18.2 million for 2014 , an increase of $ 17.2 million , or 94.8 % . this growth came primarily from growth in revenue from our nantos ( deviceconx and cos ) and eviti solutions , as well as our acquisition of hcs assets in july 2015. software and hardware revenue increased to $

cash used in operating activities of $ 74.0 million during the year ended december 31 , 2015 was a result of spending on selling , administrative structure , and research and development efforts . in the year ended december 31 , 2015 , $ 20.4 million , or 28 % , of our net loss of $ 72.0 million consisted of non-cash items , including $ 15.8 million of depreciation and amortization , $ 1.4 million in stock-based compensation , and $ 0.3 million of changes in fair value of marketable securities . cash used in operating activities during the year ended december 31 , 2015 included a $ 21.2 million decrease in deferred revenue , a $ 4.7 million decrease in related party payables , net , a $ 4.2 million increase in prepaid expenses and other assets , and a $ 4.2 million increase in deferred implementation costs , which were partially offset by an increase of $ 7.2 million in accounts payable and accrued expenses , a $ 3.6 million decrease in accounts receivable , net and , a decrease of $ 1.0 million in inventory , and a decrease of $ 0.2 million in related party receivables , net . for the year ended december 31 , 2014 , our net cash used in operating activities of $ 42.1 million consisted of a net loss of $ 84.6 million , primarily attributable to an increase in spending on selling , general and administrative expense and research and development efforts , and $ 1.0 million of cash used to fund changes in working capital , partially offset by $ 43.5 million in adjustments for non-cash items .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash used in operating activities of $ 74.0 million during the year ended december 31 , 2015 was a result of spending on selling , administrative structure , and research and development efforts . in the year ended december 31 , 2015 , $ 20.4 million , or 28 % , of our net loss of $ 72.0 million consisted of non-cash items , including $ 15.8 million of depreciation and amortization , $ 1.4 million in stock-based compensation , and $ 0.3 million of changes in fair value of marketable securities . cash used in operating activities during the year ended december 31 , 2015 included a $ 21.2 million decrease in deferred revenue , a $ 4.7 million decrease in related party payables , net , a $ 4.2 million increase in prepaid expenses and other assets , and a $ 4.2 million increase in deferred implementation costs , which were partially offset by an increase of $ 7.2 million in accounts payable and accrued expenses , a $ 3.6 million decrease in accounts receivable , net and , a decrease of $ 1.0 million in inventory , and a decrease of $ 0.2 million in related party receivables , net . for the year ended december 31 , 2014 , our net cash used in operating activities of $ 42.1 million consisted of a net loss of $ 84.6 million , primarily attributable to an increase in spending on selling , general and administrative expense and research and development efforts , and $ 1.0 million of cash used to fund changes in working capital , partially offset by $ 43.5 million in adjustments for non-cash items .
```    
 Suspicious Activity Report : - 98 - we plan to ( i ) continue investing in our infrastructure , including but not limited to solution development , sales and marketing , implementation and support , ( ii ) continue efforts to make infrastructure investments within an overall context of maintaining reasonable expense discipline , ( iii ) add new clients through maintaining and expanding sales , marketing and solution development activities , ( iv ) expand our relationships with existing clients through delivery of add-on and complementary solutions and services and ( v ) continue our commitment of service in support of our client satisfaction programs . we believe that our growing client base using our nantos and nantos apps on a daily basis is a strategic asset , and we intend to expand sales of nanthealth solutions offerings towards this client base in order to leverage this strategic asset . recent developments on june 7 , 2016 , we completed our ipo , whereby we sold 6,500,000 shares of our common stock at a public offering price of $ 14.00 per share . additionally , on june 9 , 2016 , the underwriters partially exercised their overallotment option to purchase an additional 400,000 shares of our common stock at $ 14.00 per share . we received a total of $ 83.6 million in net proceeds from our ipo , after deducting underwriting discounts and commissions and offering costs of $ 13.0 million . the offering was registered under the securities act of 1933 , as amended , on a registration statement on form s-1 ( registration no . 333-211196 ) , as amended . in december 2016 , we issued convertible notes to a related party and others for net proceeds of $ 9.9 million and $ 92.8 million , respectively , after deducting underwriting discounts and commissions and other offering costs of $ 4.2 million . please see note 12 of the notes to consolidated and combined financial statements included in item 8 of this annual report on form 10-k for further discussion of these convertible notes . recent acquisitions and investments we have made several significant acquisitions and investments in 2014 , 2015 and 2016 , which have expanded the features and functionality of nanthealth solutions , including the following : ndo in june 2014 , we acquired ndo , which provides healthcare interoperability and informatics solutions through its cos platform to address population health issues . our results of operations include the impact of the ndo acquisition as of june 2014. nantomics in june 2015 , we invested a substantial portion of our available capital in nantomics , a majority owned subsidiary of nantworks . our investment represents approximately 14.3 % of the issued and outstanding membership interests of nantomics . our relationship with nantomics provides us with access to what we believe is the nation 's only cap- and clia-certified whole genome and quantitative proteomics laboratory . healthcare solutions ( “ hcs ” ) in july 2015 , we acquired certain assets related to hcs business from harris corporation . we believe the acquired assets will help complex healthcare delivery organizations achieve better patient outcomes , clinical and administrative workflow efficiency and stronger collaboration across the continuum of care . navinet in january 2016 , we acquired navinet , which provides a secure collaboration network connecting approximately 36 health plans and which is estimated to be utilized in more than 70 % of the nation 's physicians ' offices during the fourth quarter of 2016. navinet open will serve as a nationwide scalable and secure web-based portal for patients and providers . non-gaap net loss and non-gaap net loss per share adjusted net loss and adjusted net loss per share are financial measures that are not prepared in conformity with united states generally accepted accounting principles ( u.s. gaap ) . our management believes that the presentation of non-gaap financial measures provides useful supplementary information regarding operational performance , because it enhances an investor 's overall understanding of the financial results for our core business . additionally , it provides a basis for the comparison of the financial results for our core business between current , past and future periods . other companies may define these measures in different ways . non-gaap financial measures should be considered only as a supplement to , and not as a substitute for or as a superior measure to , financial measures prepared in accordance with u.s. gaap . all loss per share numbers contained in this annual report on form 10-k are calculated based on one class of common stock and do not incorporate the effects , if any , of using the two-class method . - 99 - adjusted net loss excludes the effects of ( 1 ) loss from equity method investments , ( 2 ) stock based compensation expense , ( 3 ) intangible amortization , ( 4 ) corporate restructuring expenses , ( 5 ) bp settlement other income , ( 6 ) acquisition related compensation expense , ( 7 ) acquisition-related sales incentives , which have been recorded as contra revenue , ( 8 ) change in fair value of derivatives liability , ( 9 ) non-cash interest expense related to convertible notes , and ( 10 ) benefit for ( provision from ) income taxes adjustment includes the impact of the conversion from a limited liability corporation to a corporation , the impact of convertible notes offering and the impact of intangibles amortization . adjusted shares outstanding include series f redeemable shares as if converted on january 1 , 2014 . story_separator_special_tag this decrease was offset by a $ 1.0 million incremental increase as a result of the hcs acquisition . in 2015 , there were more projects in excess of $ 1.0 million dollars in contract value completed compared with to 2016 . we believe opportunities exist to grow software and hardware revenue through completion of both existing implementations as well as executing new sales bookings from our pipeline of opportunities . saas revenue was $ 58.4 million for the year ended december 31 , 2016 , an increase of $ 37.6 million or 181.5 % from $ 20.7 million compared to the prior year . this increase was primarily driven by increased nantos revenue including $ 1.0 million of fusionfx revenue acquired with the acquisition of hcs assets in july 2015 and revenue of $ 41.0 million from the acquisition of navinet in january 2016 in connection with saas revenue . in addition , revenue from our nantos cancer decision support ( formerly eviti ) platform solutions increased $ 1.5 million , partially offset by a $ 5.7 million decrease in revenue from other nantos interoperability platforms . maintenance revenue increased $ 3.8 million or 36.2 % from $ 10.5 million in the year ended december 31 , 2015 to $ 14.2 million for the year ended december 31 , 2016 . this increase was primarily driven by the acquisition of hcs assets in july 2015. acquired nantos ( formerly harris hcs ) maintenance customers contributed to an increase of $ 3.9 million in maintenance revenue for the year ended december 31 , 2016 . - 107 - sequencing and molecular analysis revenue during the period included revenue recognized for gps profiles for which fees are fixed and determinable under a payor agreement as well as what was recognized on a cash basis due to uncertainty over reimbursement . for the year ended december 31 , 2016 , we recorded $ 0.6 million in sequencing and molecular analysis revenue . there are significant opportunities going forward as we gain momentum in gaining coverage in the us with commercial health plans and self-insured employers and globally with supplemental benefits insurers , while at the same time building gps adoption among oncologists , including the community and academic institutions . we are aggressively expanding our sales efforts by adding seasoned sales and account management professionals in 2017. the commercial team 's efforts are focused around the development of pilots with commercial insurance payers who would agree to pay for a certain number of gps profiles , aligned with designated provider groups who will order the gps test , and reimbursement is recognized . the pipeline of pilot opportunities going into 2017 is in excess of $ 10.0 million dollars . our pipeline of self-insured employers includes opportunities with many companies listed on fortune 's 100 , as well as an alliance of 50 of the largest employers in the us . most recently , we announced a partnership with the international association of firefighters , which is significant not only because of its size , but because its incidence of cancer is much greater than the average population , and in 37 states , there are presumptive laws around job related cancer for firefighters , which has opened discussions for us related to worker 's compensation as well . other services revenue increased $ 6.5 million or 52.4 % from $ 12.4 million in 2015 to $ 18.9 million for the year ended december 31 , 2016 . this was primarily driven by the completion of a large nantos interoperability ( formerly harris hcs ) software related services project which contributed to nantos interoperability services revenue growth of $ 8.6 million for the year ended december 31 , 2016 , and incremental growth of $ 0.2 million from the navinet acquisition . these increases were partially offset by a $ 2.1 million decrease of nantos deviceconx solutions due to a decline in the number of completed large projects . we believe that significant opportunities exist for expanded cross-sell opportunities of our suite of solutions across our existing customer base , including the recently acquired hcs fusionfx and navinet customer bases . we are also integrating the cos , fusionfx and navinet product solutions , within our nantos platform , and believe that opportunities exist to cross-sell this combination of solutions to existing former hcs , fusionfx and navinet customers as well as to new customers . we also believe that our customer base and our product solutions provide unique opportunities to expand the volume of gps sequencing analysis reporting to our customer base . maintaining our current customer base will be important to our future maintenance and saas recurring revenue streams . comparison of the years ended december 31 , 2014 and 2015 total revenue increased $ 24.4 million , or 71.9 % , from $ 33.9 million for the year ended december 31 , 2014 to $ 58.3 million for the year ended december 31 , 2015 . our total revenue growth came in all of our revenue categories and was driven primarily by growth in our existing solutions including nantos ( deviceconx and cos ) , eviti and sequencing and molecular analysis , as well as our acquisition of hcs assets in july 2015. our acquisition of certain assets of hcs resulted in the contribution of $ 1.0 million , $ 1.1 million and $ 2.9 million in saas , maintenance and other services revenue , respectively , for the year ended 2015 . our total software-related revenue ( including software , hardware , and saas ) increased to $ 35.4 million for 2015 from $ 18.2 million for 2014 , an increase of $ 17.2 million , or 94.8 % . this growth came primarily from growth in revenue from our nantos ( deviceconx and cos ) and eviti solutions , as well as our acquisition of hcs assets in july 2015. software and hardware revenue increased to $

